Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

CRNX - Crinetics Pharmaceuticals, Inc.... | Finranks

Home

CRNX

(CRNX)

NMS – Цена в реальном времени. Валюта: USD

33.67

-2.64 (-7.27%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

33.65

-0.02 (-0.06%)

После закрытия: Mar 27, 2026, 5:48 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

A director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026. The sale represented 23.47% of Coelho's direct common stock holdings, reducing direct ownership from 21,300 to 16,300 shares.

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults. “The submission of our MAA for Palsonify in Brazil represents another important global milestone for this important therapy,” said Scott Struthers, Ph.D.

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to a loss of $0.88 per share a year ago.

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46 th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern Time Webcast link HERE Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with investors on Wednesday, March 11, 2026 The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at www.crinetics.com/events.

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Видео

No Data

There is no data to display